Please do not re-enter this form for patients who need supplemental doses as of 2/28/2022.

Using tixagevimab plus cilgavimab (EVUSHELD) as SARS-CoV-2 PrEP is NOT AUTHORIZED by the FDA in unvaccinated individuals for whom COVID-19 vaccination is recommended.

No patient should be denied access to Evusheld based on disability, religion, race, ethnicity, national origin, immigration status, gender/gender identity, perceived quality of life, or sexual orientation.


Loading... Loading...
You have selected an option that triggers this survey to end right now.
To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.